The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis

Huhn, 2019, Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis, Lancet, 394, 939, 10.1016/S0140-6736(19)31135-3 Goldberg, 1972, Prediction of response to phenothiazines in schizophrenia. A crossvalidation study, Arch Gen Psychiatry, 26, 367, 10.1001/archpsyc.1972.01750220077015 Galbrecht, 1968, Predicting response to phenothiazines: the right drug for the right patient, J Nerv Ment Dis, 147, 173, 10.1097/00005053-196808000-00009 Awad, 1989, Drug therapy in schizophrenia—variability of outcome and prediction of response, Can J Psychiatry, 34, 711, 10.1177/070674378903400716 Stone, 2010, Review: the biological basis of antipsychotic response in schizophrenia, J Psychopharmacol, 24, 953, 10.1177/0269881109106959 Rabinowitz, 2014, Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials, J Clin Psychiatry, 75, e308, 10.4088/JCP.13m08853 Samara, 2015, Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review, Am J Psychiatry, 172, 617, 10.1176/appi.ajp.2015.14101329 Zhu, 2017, Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses, Lancet Psychiatry, 4, 694, 10.1016/S2215-0366(17)30270-5 Krause, 2018, Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis, Eur Neuropsychopharmacol, 28, 659, 10.1016/j.euroneuro.2018.03.008 Krause, 2018, Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis, Eur Arch Psychiatry Clin Neurosci, 268, 625, 10.1007/s00406-018-0869-3 Samara, 2016, Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis, JAMA Psychiatry, 73, 199, 10.1001/jamapsychiatry.2015.2955 Krause, 2019, Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis, Eur Neuropsychopharmacol, 29, 32, 10.1016/j.euroneuro.2018.11.1105 Krause, 2018, Antipsychotic drugs for elderly patients with schizophrenia: a systematic review and meta-analysis, Eur Neuropsychopharmacol, 28, 1360, 10.1016/j.euroneuro.2018.09.007 Higgins, 2008 Tong, 2018, Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study, BMC Med Res Methodol, 18, 96, 10.1186/s12874-018-0554-2 Leucht, 2022, Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia, Eur Arch Psychiatry Clin Neurosci, 272, 1, 10.1007/s00406-021-01378-1 McMahon, 2008, Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research, Schizophr Bull, 34, 292, 10.1093/schbul/sbm152 Gardner, 2010, International Consensus Study of Antipsychotic Dosing, Am J Psychiatry, 167, 686, 10.1176/appi.ajp.2009.09060802 derSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 Amr, 2013, Efficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia: a randomized clinical trial, Int Arch Med, 6, 47, 10.1186/1755-7682-6-47 Safa, 2008, Metabolic effects of olanzapine and risperidone in patients with psychotic disorders, Int J Psychiatry Clin Pract, 12, 299, 10.1080/13651500802155337 Gureje, 2003, Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand, Schizophr Res, 61, 303, 10.1016/S0920-9964(02)00226-8 Marques, 2014, How antipsychotics impact the different dimensions of schizophrenia: a test of competing hypotheses, Eur Neuropsychopharmacol, 24, 1279, 10.1016/j.euroneuro.2014.04.001 McCutcheon, 2020, Schizophrenia—an overview, JAMA Psychiatry, 77, 201, 10.1001/jamapsychiatry.2019.3360 de Bartolomeis, 2022, Present and future antipsychotic drugs: a systematic review of the putative mechanisms of action for efficacy and a critical appraisal under a translational perspective, Pharmacol Res, 176, 106078, 10.1016/j.phrs.2022.106078 Jauhar, 2019, Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study, Mol Psychiatry, 24, 1502, 10.1038/s41380-018-0042-4 Mizuno, 2020, Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis, Neuropsychopharmacology, 45, 622, 10.1038/s41386-019-0577-3 Zhu, 2017, How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis, Eur Neuropsychopharmacol, 27, 835, 10.1016/j.euroneuro.2017.06.011 Galderisi, 2018, Negative symptoms of schizophrenia: new developments and unanswered research questions, Lancet Psychiatry, 5, 664, 10.1016/S2215-0366(18)30050-6 McCutcheon, 2019, Schizophrenia, dopamine and the striatum: from biology to symptoms, Trends Neurosci, 42, 205, 10.1016/j.tins.2018.12.004 Németh, 2017, Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial, Lancet, 389, 1103, 10.1016/S0140-6736(17)30060-0 Schoemaker, 1997, Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity, J Pharmacol Exp Ther, 280, 83 Kane, 1988, Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine, Arch Gen Psychiatry, 45, 789, 10.1001/archpsyc.1988.01800330013001 McEvoy, 2007, Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison, Am J Psychiatry, 164, 1050, 10.1176/ajp.2007.164.7.1050 Lieberman, 2003, Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine, Neuropsychopharmacology, 28, 995, 10.1038/sj.npp.1300157 Alvarez-Jiménez, 2008, Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal, CNS Drugs, 22, 547, 10.2165/00023210-200822070-00002 Corves, 2014, Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?, Acta Psychiatr Scand, 130, 40, 10.1111/acps.12231 Krause, 2019, Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: a systematic review, pairwise and network meta-analysis, Eur Neuropsychopharmacol, 29, 1003, 10.1016/j.euroneuro.2019.07.130 McCutcheon, 2022, Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis, World Psychiatry, 21, 287, 10.1002/wps.20977 Furukawa, 2015, Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies, JAMA Psychiatry, 72, 14, 10.1001/jamapsychiatry.2014.2127 Tollefson, 1997, Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial, Am J Psychiatry, 154, 457, 10.1176/ajp.154.4.457 Swartz, 2008, The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study, Schizophr Res, 100, 39, 10.1016/j.schres.2007.11.034 Fruth, 2022, New insight into the CATIE study by constrained confidence partitioning. An innovative technique towards personalized antipsychotic drug therapy in schizophrenia treatment, Schizophr Res, 239, 192, 10.1016/j.schres.2021.11.020